Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Inmed Pharmaceuticals Inc (INM)

Inmed Pharmaceuticals Inc (INM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
InMed Announces Results of 2024 Annual General Meeting Newsfile - Wed Dec 18, 7:10PM CST

Vancouver, British Columbia--(Newsfile Corp. - December 18, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary...

INM : 4.40 (+6.25%)
InMed Enters Into Standby Equity Purchase Agreement Newsfile - Tue Dec 17, 3:58PM CST

Vancouver, British Columbia--(Newsfile Corp. - December 17, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary...

INM : 4.40 (+6.25%)
InMed Announces Publication of Study on Anti-Inflammation by Modulation of Endocannabinoid System Newsfile - Tue Nov 19, 6:36AM CST

Cannabinol modulates distinct endocannabinoid system elements and exerts anti-inflammatory effectsSupports therapeutic potential of cannabinol for inflammatory skin diseases such as psoriasis, atopic dermatitis...

INM : 4.40 (+6.25%)
InMed Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update Newsfile - Thu Nov 14, 3:56PM CST

Vancouver, British Columbia--(Newsfile Corp. - November 14, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary...

INM : 4.40 (+6.25%)
InMed Announces Share Consolidation to Satisfy Nasdaq Listing Rules Newsfile - Fri Nov 8, 3:56PM CST

Vancouver, British Columbia--(Newsfile Corp. - November 8, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary...

INM : 4.40 (+6.25%)
InMed Pharmaceuticals Announces Decision by NASDAQ Hearings Panel to Grant Exception to Implement Share Consolidation to Satisfy NASDAQ Listing Rules Newsfile - Tue Nov 5, 7:40AM CST

Vancouver, British Columbia--(Newsfile Corp. - November 5, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary...

INM : 4.40 (+6.25%)
InMed Pharmaceuticals Files Additional Patent Application for INM-901 in the Treatment of Neurodegenerative Conditions Including Alzheimer's Disease Newsfile - Mon Oct 28, 6:44AM CDT

Vancouver, British Columbia--(Newsfile Corp. - October 28, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary...

INM : 4.40 (+6.25%)
InMed to Participate in Fierce Biotech Webinar on Neuroinflammation in Alzheimer's Disease Newsfile - Thu Oct 24, 7:14AM CDT

Vancouver, British Columbia--(Newsfile Corp. - October 24, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary...

INM : 4.40 (+6.25%)
InMed Appoints Dr. Barry Greenberg, Johns Hopkins University School of Medicine, to its Scientific Advisory Board Newsfile - Tue Oct 22, 7:14AM CDT

Vancouver, British Columbia--(Newsfile Corp. - October 22, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary...

INM : 4.40 (+6.25%)
InMed Pharmaceuticals Reports Full Year Fiscal 2024 Financial Results and Provides Business Update Newsfile - Mon Sep 30, 7:12AM CDT

Advances INM-901 program targeting several biological pathways associated with Alzheimer's diseaseFurther develops INM-089 demonstrating neuroprotection in the treatment of dry Age-related Macular Degeneration$4.6M...

INM : 4.40 (+6.25%)

Barchart Exclusives

Oracle Stock Is Off Its Highs and Could Be Cheap Here Barchart - 1 hour ago
Oracle Corp. produced higher revenue in Q2 but lower free cash flow and FCF margins. However, ORCL stock is now off its highs and could be undervalued here. Shorting out-of-the-money puts is one way to play it. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot